[The nitrosative effect of peripheral ischemia-reperfusion on lung and preventive of caffeic acid phenethyl ester].
Ischemia-reperfusion (IR) is characterized by microvascular disfunction and this involves both direct effected organ and remote organ by systemic inflammatory response. These remote effects of IR are most frequently observed in the lung and cardiovascular system. In this study we aim to determine lung damage which induced IR, and endothelial and microvascular disfunction using nitrosative markers. Previous studies suggest that caffeic acid phenethyl ester (CAPE) has some antioxidant effects. Therefore, we also investigated whether it has a role associated with nitric oxide during IR condition. Twenty-two adult male Wistar rats were divided into three groups: control (n= 7), IR (n= 7), and CAPE + IR (n= 8). 8 h IR period was performed on right hindlimb in the IR and the CAPE with IR group. In the CAPE with IR group, animals received CAPE 10 microM 1 h before the reperfusion. At the end of the reperfusion period, blood, bronchoalveolar lavage (BAL) and lung tissue were obtained, and were used for biochemical and histopathological examination. There was a significantly elevation in serum nitrate, BAL MPO, and leukocyte infiltration in the lung in the IR group compared to the CAPE + IR group. But, serum nitrite and lung 3-NT levels were not different between these groups. While nitrate (p< 0.0001), MPO (p< 0.0001) and leukocyte infiltration (chi2= 27.163, p= 0.0001), reduce by using CAPE before reperfusion, tissue 3-NT levels did not change. In conclusion, peripheral IR leads to systemic inflammatory responses and endothelial disfunction-induced NO production, and these harmful effects may reduced by CAPE.
Calikoğlu
Mukadder
M
Pulmonary Diseases, Faculty of Medicine, Mersin University, Mersin, Turkey. mcalikoglu@hotmail.com
Unlü
Ali
A
Sucu
Nehir
N
Aktaş
Savaş
S
Tamer
Lülüfer
L
Calikoğlu
Ilker
I
D000818:Animals; D001992:Bronchoalveolar Lavage Fluid; D002109:Caffeic Acids / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D002199:Capillary Permeability / Q000187:drug effects; D016207:Cytokines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D006614:Hindlimb / Q000098:blood supply* / Q000503:physiopathology; D008168:Lung / Q000098:blood supply / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D020556:Neutrophil Infiltration / Q000187:drug effects; D010626:Phenylethyl Alcohol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000503:physiopathology; D012128:Respiratory Distress Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D014111:Tourniquets; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000378:metabolism
D002109:Caffeic Acids; D016207:Cytokines; D016328:NF-kappa B; C002744:3-nitrotyrosine; D014443:Tyrosine; D008315:Malondialdehyde; C055494:caffeic acid phenethyl ester; D010626:Phenylethyl Alcohol